Propanc Biopharma, Inc. PPCB
Propanc Biopharma, Inc. (Nasdaq: PPCB) is an oncology drug developer. Its lead program, PRP (proenzyme therapy: trypsinogen and chymotrypsinogen), is in Pre-clinical for recurrence/metastasis prevention in pancreatic, ovarian and colorectal cancers (solid tumors). Its next catalyst on record is PRP: Submit clinical trial application (CTA) for First-In-Human study (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PRP — Submit clinical trial application (CTA) for First-In-Human study (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PRP | advanced solid tumors (pancreatic, ovarian, colorectal) | protein/peptide | Pre-clinical |
| POP1 program (backup proenzyme compound) | cancer | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.